Dynavax Reports 34% Revenue Increase in Q1 2025, HEPLISAV-B® Sales Rise by 36%, Improves Adjusted EBITDA from Negative $7M to Negative $4M

Reuters

2025/05/08

Dynavax Reports 34% Revenue Increase in Q1 2025, HEPLISAV-B® Sales Rise by 36%, Improves Adjusted EBITDA from Negative $7M to Negative $4M

Dynavax Technologies Corporation has reported its financial results for the first quarter of 2025, highlighting a significant increase in revenue and market share. Total revenue reached $68.2 million, marking a 34% rise compared to $50.8 million in the same quarter of 2024. The net product revenue for HEPLISAV-B® was $65 million, representing a 36% increase from $47.8 million in the previous year's first quarter. The company's HEPLISAV-B® total estimated U.S. market share also grew to approximately 43%, up from about 41% in Q1 2024. Adjusted EBITDA improved to negative $4 million, compared to negative $7 million in Q1 2024, with expectations for Adjusted EBITDA to reach at least $75 million by the end of 2025. Dynavax has executed over 85% of its $200 million share repurchase program, with $172 million completed as of May 5, 2025. The company continues to advance its vaccine pipeline, leveraging its proprietary CpG 1018 adjuvant, and has announced new pipeline programs alongside their ongoing shingles and plague vaccine initiatives.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Dynavax Technologies Corporation published the original content used to generate this news brief via PR Newswire (Ref. ID: SF82793) on May 07, 2025, and is solely responsible for the information contained therein.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2533299389"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2533299389\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2533299389?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-05-08 05:11","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2533299389","market":"us","top_or_hot":-1,"title":"Dynavax Reports 34% Revenue Increase in Q1 2025, HEPLISAV-B® Sales Rise by 36%, Improves Adjusted EBITDA from Negative $7M to Negative $4M","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Dynavax Reports 34% Revenue Increase in Q1 2025, HEPLISAV-B® Sales Rise by 36%, Improves Adjusted EBITDA from Negative $7M to Negative $4M\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Dynavax Technologies Corporation has reported its financial results for the first quarter of 2025, highlighting a significant increase in revenue and market share. Total revenue reached $68.2 million, marking a 34% rise compared to $50.8 million in the same quarter of 2024. The net product revenue for HEPLISAV-B® was $65 million, representing a 36% increase from $47.8 million in the previous year's first quarter. The company's HEPLISAV-B® total estimated U.S. market share also grew to approximately 43%, up from about 41% in Q1 2024. Adjusted EBITDA improved to negative $4 million, compared to negative $7 million in Q1 2024, with expectations for Adjusted EBITDA to reach at least $75 million by the end of 2025. Dynavax has executed over 85% of its $200 million share repurchase program, with $172 million completed as of May 5, 2025. The company continues to advance its vaccine pipeline, leveraging its proprietary CpG 1018 adjuvant, and has announced new pipeline programs alongside their ongoing shingles and plague vaccine initiatives.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Dynavax Technologies Corporation published the original content used to generate this news brief via PR Newswire (Ref. ID: SF82793) on May 07, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Dynavax Reports 34% Revenue Increase in Q1 2025, HEPLISAV-B® Sales Rise by 36%, Improves Adjusted EBITDA from Negative $7M to Negative $4M</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nDynavax Reports 34% Revenue Increase in Q1 2025, HEPLISAV-B® Sales Rise by 36%, Improves Adjusted EBITDA from Negative $7M to Negative $4M\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-05-08 05:11</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Dynavax Reports 34% Revenue Increase in Q1 2025, HEPLISAV-B® Sales Rise by 36%, Improves Adjusted EBITDA from Negative $7M to Negative $4M\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Dynavax Technologies Corporation has reported its financial results for the first quarter of 2025, highlighting a significant increase in revenue and market share. Total revenue reached $68.2 million, marking a 34% rise compared to $50.8 million in the same quarter of 2024. The net product revenue for HEPLISAV-B® was $65 million, representing a 36% increase from $47.8 million in the previous year's first quarter. The company's HEPLISAV-B® total estimated U.S. market share also grew to approximately 43%, up from about 41% in Q1 2024. Adjusted EBITDA improved to negative $4 million, compared to negative $7 million in Q1 2024, with expectations for Adjusted EBITDA to reach at least $75 million by the end of 2025. Dynavax has executed over 85% of its $200 million share repurchase program, with $172 million completed as of May 5, 2025. The company continues to advance its vaccine pipeline, leveraging its proprietary CpG 1018 adjuvant, and has announced new pipeline programs alongside their ongoing shingles and plague vaccine initiatives.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Dynavax Technologies Corporation published the original content used to generate this news brief via PR Newswire (Ref. ID: SF82793) on May 07, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"DVAX","symbol_name":"德纳维制药","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250507:nNDL7sqdKS:1","article_id":"2533299389","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2533299389","pubTimestamp":1746652294,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Dynavax Reports 34% Revenue Increase in Q1 2025, HEPLISAV-B Sales Rise by 36%, Improves Adjusted EBITDA from Negative $7M to Negative $4M. Dynavax Technologies Corporation has reported its financial results for the first quarter of 2025, highlighting a significant increase in revenue and market share. Total revenue reached $68.2 million, marking a 34% rise compared to $50.8 million in the same quarter of 2024. The net product revenue for HEPLISAV-B was $65 million, representing a 36% increase from $47.8 million in the previous year's first quarter. The company's HEPLISAV-B total estimated U.S. market share also grew to approximately 43%, up from about 41% in Q1 2024. Adjusted EBITDA improved to negative $4 million, compared to negative $7 million in Q1 2024, with expectations for Adjusted EBITDA to reach at least $75 million by the end of 2025. Dynavax has executed over 85% of its $200 million share repurchase program, with $172 million completed as of May 5, 2025. The company continue","collect":0,"end_time":0,"defaultTopTitle":"","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"DVAX":"德纳维制药"},"translate_title":"Dynavax报告2025年第一季度收入增长34%，HEPLISAV-B®销售额增长36%，调整后EBITDA从负700万美元提高到负400万美元","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"DVAX":0.9},"content_text":"Dynavax Reports 34% Revenue Increase in Q1 2025, HEPLISAV-B® Sales Rise by 36%, Improves Adjusted EBITDA from Negative $7M to Negative $4M\n    \n\n        Dynavax Technologies Corporation has reported its financial results for the first quarter of 2025, highlighting a significant increase in revenue and market share. Total revenue reached $68.2 million, marking a 34% rise compared to $50.8 million in the same quarter of 2024. The net product revenue for HEPLISAV-B® was $65 million, representing a 36% increase from $47.8 million in the previous year's first quarter. The company's HEPLISAV-B® total estimated U.S. market share also grew to approximately 43%, up from about 41% in Q1 2024. Adjusted EBITDA improved to negative $4 million, compared to negative $7 million in Q1 2024, with expectations for Adjusted EBITDA to reach at least $75 million by the end of 2025. Dynavax has executed over 85% of its $200 million share repurchase program, with $172 million completed as of May 5, 2025. The company continues to advance its vaccine pipeline, leveraging its proprietary CpG 1018 adjuvant, and has announced new pipeline programs alongside their ongoing shingles and plague vaccine initiatives.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Dynavax Technologies Corporation published the original content used to generate this news brief via PR Newswire (Ref. ID: SF82793) on May 07, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}